Testing how cancer vaccines work in B-cell blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study measures how well certain vaccines stimulate the immune system in people with B-cell blood cancers such as CLL and different types of lymphoma or Waldenström macroglobulinemia. It may help doctors better predict who will benefit most from vaccination and improve vaccine planning for these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have one of these diagnoses: CLL, FL, MCL, MZL, NHL not otherwise specified, or Waldenström (WM)
- You must fit the study arm based on your current treatment plan and vaccine you receive
- If you previously had a hepatitis-B vaccine, you must have documented negative blood test results showing no response
- You can understand the study and sign consent
- You are not pregnant, and you do not have a history of a severe allergic reaction to vaccines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the Shingrix vaccine prevents shingles in people with CLL (a type of blood cancer). It will look at how well the vaccine works and helps your immune system fight the virus.
This trial tests a series of two pneumococcal vaccines (PCV20 and PPSV23) in people with CLL-related immune weakness. It aims to see how well the vaccines work and how safe they are for preventing serious lung infections.
This study checks how your immune system responds after getting a vaccine. It focuses on people with different types of lymphoma, aiming to learn which immune responses can be measured and whether the vaccines are safe for you.
This trial compares two vaccination plans to see which one works better for preventing pneumococcal infections after lymphoma chemotherapy. You may be randomly assigned to one of the vaccine strategies, and the study checks your immune response.
This early-phase trial tests a personalized-style vaccine (called VSV-hIFNβ-NIS) given alone or with other cancer-fighting medicines, including drugs that help the immune system attack. It is designed for people with certain relapsed or hard-to-treat multiple myeloma, acute myeloid leukemia, or lymphomas, to see if the treatment can shrink tumors and improve outcomes.
This trial tests a new mRNA treatment that helps your immune cells target and attack lymphoma cells. It's for people whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.